Andere talen CanSino Biologics Inc.

Aandelen

6185

CNE100003F01

Vertraagde tijd Hong Kong S.E. Andere beurzen 10:08:05 31-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
20,35 ^HKD	-3,78%		-7,71%	-13,59%

31/05	CanSino Biologics Inc. kondigt aan dat Nisa Bernice Wing-Yu LEUNG ontslag heeft genomen als niet-uitvoerend bestuurder en lid van het benoemingscomité	CI
21/05	Cansino Biologics investeert 160 miljoen yuan in gestructureerde deposito's van China Bohai Bank	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

CanSino Biologics Inc. Announces Resignation of Nisa Bernice Wing-Yu LEUNG as Non-Executive Director and Member of the Nomination Committee	31/05
Cansino Biologics Invests 160 Million Yuan in China Bohai Bank’s Structured Deposits	21/05
CanSino Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	29/04
CanSino Biologics Inc. Obtains Clinical Trial Approval Granted by the National Medical Products Administration of the People's Republic of China	22/04
Cansino Biologics Begins Phase III Clinical Trials for Tetanus Drug	21/03
Cansino Biologics Inc. Announces Initiation of Phase III Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine	20/03
Cansino Biologics Inc. Announces Acceptance of Drug Registration Application for 13-Valent Pneumococcal Conjugate Vaccine	28/02
CanSino Biologics' Loss Widens in 2023, Misses EPS, Revenue Estimates; Shares Rise 4%	26/02
Cansino Biologics Inc. Announces Board and Committee Elections	23/02
CanSino Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	23/02
CanSino Biologics Deconsolidates CanSino SPH	02/02
CanSino Biologics' Loss to Widen in 2023; Shares Drop 5%	31/01
CanSino Biologics' 13-Valent Pneumococcal Vaccine Trial Shows Positive Results	31/01
Cansino Biologics Inc. Provides Earnings Guidance for Year Ended December 31, 2023	30/01
CanSino Biologics Inc. Obtains the Final Report of Phase III Clinical Trial Of 13-Valent Pneumococcal Conjugate Vaccine	30/01
Cansino Biologics Inc. Announces Phase I Clinical Trial and Completion of First Patient Case for Recombinant Poliomyelitis Vaccine	15/01
CanSino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine	20/12
Scientists see risk of lost opportunity for long COVID research in China	14/12
Cansino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Patient Enrollment for TDCP Adolescent and Adult	06/12
CanSino Biologics Inc. announces Recombinant Covid-19 Xbb.1.5 Variant Vaccine Forinhalation (Adenovirus Type 5 Vector) Included for Emergency Use	03/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Headlines

CanSino Biologics over AstraZeneca-deal, inkomsten

31 augustus 2023 om 12:08 uur